Human Microbiome Market (4th Edition): Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy By L Vijay, November 23, 2022. The human microbiome remained a largely unexplored area until 2007 when the Human Microbiome Project (HMP) was initiated. The project was undertaken to understand the concept of core human microbiome and its compatibility with the host
The Untapped Potential of Microbiome Mining in Drug Discovery and Precision Medicine By Ross Youngs, November 17, 2022. Through the innovative practice of microbiome mining, scientists and researchers will be able to harvest and study microbiome molecules at an industrial scale for the first time. Life science is on the verge of ushering in the
Summary – In this episode, Artur and Marian discuss what is required for scaling technologies and how to achieve breakthroughs. To give a practical example, they interview Ross Youngs, CEO, and founder of Biosortia, who describes his company’s scaling and breakthrough in the field of microbiome harvesting.
Roche Doubles Down on Jnana’s RAPID Platform in $2B Deal (November 15, 2022) | By Alex Keown. It’s been a lucrative Tuesday for Jnana Therapeutics after it forged a second small molecule discovery and development collaboration and licensing agreement with Roche valued at up to $2 billion. The company also raised $107 million in a
URI Pharmacy study seeks to identify new toxins in algal blooms Assistant Professor Matthew Bertin’s study funded by $400,000 federal grant focuses on freshwater lakes, rivers By Patrick Luce, November 14, 2022. KINGSTON, R.I. — Nov. 14, 2022 — Bacterial algal blooms and the toxins they produce are a persistent problem in freshwater lakes and
Sanofi taps into Insilico Medicine’s AI platform in deal worth up to $1.2bn (November 10, 2022) | By Rachel Arthur. Sanofi and Insilico Medicine have announced a multi-year, multi-target strategic research collaboration: leveraging Insilico’s ‘Pharma.AI’ platform to advance drug development for up to six new targets.
Juvena Therapeutics Raises $41M in Series A Funding November 8, 2022 Juvena Therapeutics, a Redwood City, CA-based biotechnology company, raised $41M in Series A funding. The round was led by Mubadala Capital and Horizons Ventures, with participation from Bison Ventures, Manta Ray Ventures, IRONGREY, Alumni Ventures, Plum Alley, Jeff Dean, Transform VC, Karl Pfleger, BoxOne
I, Microbiome: A Secret to a Healthy and Balanced Human Body November 03, 2022. Vladimir Jakovljevic. Thank you for including Industrial Scale Microbiome Mining and Biosortia in your new book. Biosortia is excited about the microbiome and the opportunities this virtually unexplored space will deliver to humanity. Therapeutics, agriculture, sustainability, longevity, advanced energy, carbon capture,
Summary – Join me and Ross Youngs, a successful innovator, serial entrepreneur, and the founder and CEO of Biosortia, Inc. – Microbiomics, for great insights on how AI and technology support academia, accelerate discovery, and what this means for humanity.
